EXCLUSIVE: Pasithea Therapeutics Launches First Ketamine Clinic In The UK

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a company in the psychedelics space, will launch its first U.K.-based ketamine infusion clinic.

The company went public with a $24 million IPO in the Nasdaq last month and is focused on research and discovery of new and effective treatments for psychiatric and neurological disorders.

What To Know: For the launch of its first U.K. clinic, Pasithea’s wholly-owned subsidiary, Pasithea Clinics, has partnered with ZEN Healthcare to offer intravenous ketamine therapy to patients suffering from treatment-resistant disorders.

The treatment will initially be …

Full story available on Benzinga.com

More EXCLUSIVE: Pasithea Therapeutics Launches First Ketamine Clinic In The UK